MS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Morgan Stanley is not a strong buy for a beginner long-term investor at this moment. While the company has demonstrated solid financial performance and has positive analyst sentiment, the technical indicators suggest a bearish trend, and there is no significant trading signal from Intellectia Proprietary Trading Signals. Additionally, recent Congress trading data shows a cautious attitude with more selling activity, and the options data indicates a slightly bearish sentiment. Given the user's impatience and unwillingness to wait for optimal entry points, it is better to hold off on buying this stock now.
The MACD histogram is negative and expanding (-1.453), indicating a bearish trend. The RSI is at 22.288, which is neutral but leaning towards oversold territory. The moving averages are converging, showing no clear direction. The current price ($168.06) is near the S1 support level ($168.863), suggesting limited downside risk but also no strong upward momentum.
Strong Q4 financial performance with revenue up 11.32% YoY, net income up 19.25% YoY, and EPS up 20.72% YoY.
Positive analyst sentiment, with multiple price target increases and favorable ratings.
Morgan Stanley's diversified business model and strong Wealth Management division performance.
Bearish technical indicators, including negative MACD and converging moving averages.
Congress trading data shows 4 recent sale transactions and no purchases, indicating caution.
Broader market concerns, including rising financing costs and regulatory pressures on banks.
Morgan Stanley delivered strong Q4 2025 results, with revenue increasing to $28.86 billion (up 11.32% YoY), net income rising to $4.25 billion (up 19.25% YoY), and EPS growing to $2.68 (up 20.72% YoY). Gross margin also improved slightly to 58.08%.
Analysts have a positive outlook on Morgan Stanley, with multiple price target increases in January 2026. Keefe Bruyette raised the target to $210, RBC Capital to $207, BofA to $220, Wolfe Research to $211, and Barclays to $219. Most analysts maintain Outperform or Buy ratings, citing strong financial performance and a diversified business model. However, Wells Fargo downgraded Morgan Stanley Direct Lending, highlighting some credit risks.
